Tag Archives: Financial Times

Sanofi-Aventis shows 2008 figures and new Top Executive Positions.

Written by Xavier Tello This morning sanofi-aventis has released to the press its financial results for 2008. The results, conservative (as expected) but “above guidance” are shown bellow.   Key comments: 2008 Net Sales: € 27,568 M (+ 3.7%) EPS at €5.49 … Continue reading

Posted in Alta Dirección, Mercadotecnia, Planeac. Estratégica, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment

P&G will sell its Pharmaceutical Unit

According to financial-specialized media, P&G is seriously considering to sell its pharmaceutical unit. This are the first confirmed news of the American consumer company about letting this important branch go, despite 2006 and last year’s news of cutting its R&D … Continue reading

Posted in Alta Dirección, Mercadotecnia, Planeac. Estratégica, Salud, Ventas | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Con 4,000 M de € en la bolsa, Sanofi-Aventis busca ya una adquisición.

El día de hoy, el Financial Times publica una nota en la cual dice que sanofi-aventis estaría ya asesorándose de banqueros para llevar acabo -lo antes posible- alguna adquisición. De primera intención, se cita a Chris Viehbacher, flamante CEO de la Empresa, quien … Continue reading

Posted in Alta Dirección, Mercadotecnia, Planeac. Estratégica, Salud | Tagged , , , , , , , , , , , , , , | Leave a comment

Obama’s frustration with IT at the White House; a reflection of top Businesses?

An interesting point has been brought out yesterday by the Washington Post, regarding the new Presidential staff been frustrated by the lack of updating in the White House IT. Furthermore, as Obama’s campaign was based in great proportion in Web … Continue reading

Posted in Alta Dirección, Tecnología | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | 1 Comment

Pfizer podría comprar a Wyeth ya.

De acuerdo con una nota del Financial Times, Pfizer se encuentra finalizando pláticas para la adquisición de su rival Wyeth en una operación cercana a los $60,000 M de USD; 60% en cash y 40% en acciones. Esta sería la … Continue reading

Posted in Alta Dirección, Mercadotecnia, Salud, Ventas | Tagged , , , , , , , , , , , , | Leave a comment